Table 1 Detailed baseline characteristics of patients included (n = 752)
Parameters | Statistic | Obs | |
|---|---|---|---|
Age | 67 (61,73) | Median, IQR | |
PSA (ng/mL) | 11.89 (7.385,24.3) | Median, IQR | |
Prostate Volume (mL) | 80.92 (56,119) | Median, IQR | |
PSA density | 0.15 (0.08,0.33) | Median, IQR | |
PI-RADS scores (highest) | |||
≤ 2 | 123 (16.4%) | n (%) | |
3 | 308 (41.0%) | n (%) | |
≥ 4 | 321 (42.6%) | n (%) | |
mSBRS scores | |||
< 4 | 357 (47.5%) | n (%) | |
≥ 4 | 395 (52.5%) | n (%) | |
Number of targeted biopsy targets on MRI | |||
1 | 424 (56.4%) | n (%) | |
2 | 153 (20.3%) | n (%) | |
3 | 152 (20.2%) | n (%) | |
4 | 23 (3.1%) | n (%) | |
Risk stratification based on risk level determined through predictive nomogram (PCA risk ≥ 0.5 or not) | |||
High (PCA risk ≥ 0.5) | 354 (47.1%) | n (%) | |
Low (PCA risk<0.5) | 398 (52.9%) | n (%) |